VIVUS Announces Scientific Presentations

VIVUS Announces Scientific Presentations

MOUNTAIN VIEW, Calif., May 22, 2013 (GLOBE NEWSWIRE) -- VIVUS, Inc.
(Nasdaq:VVUS), a biopharmaceutical company commercializing and developing
innovative, next-generation therapies to address unmet needs in obesity and
sexual health, today announced the following scientific presentations:

Conference

2013 Annual Scientific Meeting of the American Society of Hypertension (ASH)
May 15-18, 2013
San Francisco Marriott, San Francisco, CA

Date / Time

Oral Presentation Date: Saturday, May 18, 2013 at 8:30am
Session Location: San Francisco Marriott, Yerba Buena Ballroom 9

Presentation Title

Cardiovascular Effects Based on Magnitude of Weight Loss in Obese/Overweight
Subjects With Hypertension Receiving Phentermine and Topiramate
Extended-Release

Authors:

George Bakris, MD, FASH, FASN^a; Michael H. Davidson, MD, FACC, FACP^a; Alok
K. Gupta, MD, FTOS, FASH, FAAFP^b

Affiliations:

^aASH Comprehensive Hypertension Center, The University of Chicago Pritzker
School of Medicine, Chicago, IL; ^bClinical Research, Pennington Biomedical
Research Center, Louisiana State University System, Baton Rouge, LA

Conference

166^th Annual Meeting of the American Psychiatric Association (APA)
May 18-22, 2013
Moscone Center, San Francisco, CA

Date / Time

Poster Presentation Date: Monday, May 20, 2013 from 2:00pm-4:00pm
Session Location: Moscone South Exhibit Hall A-C
Poster Session: 9
Poster number: NR9-54

Presentation Title

Weight Loss and Depression in Overweight/Obese Subjects With a History of
Depression Receiving Phentermine and Topiramate Extended-Release

Authors:

Patrick M. O'Neil, PhD^a; Craig A. Peterson, MS^b

Affiliations:

^aMedical University of South Carolina, Charleston, SC; ^bVIVUS, Inc.,
Mountain View, CA

Conference

18^th Annual International Meeting of the International Society for
Pharmacoeconomics and Outcomes Research (ISPOR)
May 18-22, 2013
Sheraton New Orleans, New Orleans, LA, USA

Poster1

Date / Time

Poster Presentation Date: Monday, May 20, 2013 from 3:45pm – 7:45 pm with
discussion hour from 6:45pm-7:45pm
Poster Session: II
Poster Number: PSY13

Presentation Title

Effects of Phentermine and Topiramate Extended-Release Treatment on Weight
Loss When Stratified by Baseline Body Mass Index Over 1 Year

Author(s)

Authors: Donna Ryan, MD^a; Timothy Church, MD^a; Sunil Karnawat^b; Barbara
Troupin, MD^b

Affiliations:

^aPennington Biomedical Research Center, Louisiana State University System,
Baton Rouge, LA, USA

^bVIVUS, Inc., Mountain View, CA, USA

Poster 2

Date / Time

Poster Presentation Date: Monday, May 20, 2013 from 3:45pm – 7:45 pm with
discussion hour from 6:45pm-7:45pm
Poster Session: II
Poster Number: PSY4

Presentation Title

The Potential Cost Savings Associated With Preventing the Development of
Hypertension, Diabetes, and Dyslipidemia in an Obese Population

Author(s)

Authors: Carlton R. ^ a; Bramley T. ^ a; Zagadailov E^a.; Karnawat S. ^ b

Affiliations:

^aXcenda, Palm Harbor, FL; ^bVIVUS, Inc., Mountain View, CA

About Qsymia

Qsymia^® (phentermine and topiramate extended-release) capsules CIV is
approved in the U.S. and is indicated as an adjunct to a reduced-calorie diet
and increased physical activity for chronic weight management in adults with
an initial body mass index (BMI) of 30 kg/m2 or greater (obese) or 27 kg/m2 or
greater (overweight) in the presence of at least one weight-related medical
condition such as high blood pressure, type 2 diabetes, or high cholesterol.

The effect of Qsymia on cardiovascular morbidity and mortality has not been
established. The safety and effectiveness of Qsymia in combination with other
products intended for weight loss, including prescription and over-the-counter
drugs, and herbal preparations, have not been established.

Important Safety Information

Qsymia^® (phentermine and topiramate extended-release) capsules CIV is
contraindicated in pregnancy; in patients with glaucoma; in hyperthyroidism;
in patients receiving treatment or within 14 days following treatment with
monoamine oxidase inhibitors (MAOIs); or in patients with hypersensitivity to
sympathomimetic amines, topiramate, or any of the inactive ingredients in
Qsymia.

Qsymia can cause fetal harm. Females of reproductive potential should have a
negative pregnancy test before treatment and monthly thereafter and use
effective contraception consistently during Qsymia therapy. If a patient
becomes pregnant while taking Qsymia, treatment should be discontinued
immediately, and the patient should be informed of the potential hazard to the
fetus.

The most commonly observed side effects in controlled clinical studies, 5% or
greater and at least 1.5 times placebo, include paraesthesia, dizziness,
dysgeusia, insomnia, constipation, and dry mouth.

About VIVUS

VIVUS is a biopharmaceutical company commercializing and developing
innovative, next-generation therapies to address unmet needs in obesity and
sexual health. For more information about the company, please visit
www.vivus.com.

Certain statements in this press release are forward-looking within the
meaning of the Private Securities Litigation Reform Act of 1995. These
statements may be identified by the use of forward-looking words such as
"anticipate," "believe," "forecast," "estimate," "expect," "intend," "likely,"
"may," "plan," "potential," "predict," "opportunity" and "should," among
others. There are a number of factors that could cause actual events to differ
materially from those indicated by such forward-looking statements. VIVUS does
not undertake an obligation to update or revise any forward-looking
statements. Investors should read the risk factors set forth in VIVUS's Form
10-K for the year ending December 31, 2012, as amended by the Form 10-K/A
filed on April 30, 2013, and periodic reports filed with the Securities and
Exchange Commission.

CONTACT: VIVUS, Inc.
         Dana B. Shinbaum
         Corporate Development
         & Investor Relations
         shinbaum@vivus.com
        
         Investor Relations:
         The Trout Group
         Brian Korb
         bkorb@troutgroup.com
         646-378-2923
 
Press spacebar to pause and continue. Press esc to stop.